Request Free Sample ×
Germany Pharmacy Benefit Management Services Market Research Report-Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Germany Pharmacy Benefit Management Services Market

ID: MRFR/Pharma/48951-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

Germany Pharmacy Benefit Management Services Market Research Report By Service Type (Claims Management, Formulary Management, Drug Utilization Review, Medication Therapy Management), By End User (Pharmacies, Health Plans, Employers, Public Sector), By Service Provider (Standalone Pharmacy Benefit Managers, Health Insurance Companies, Integrated Health Systems) and By Operating Model (Fully-Managed Services, Pass-Through Services, Hybrid Services) -Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Germany Pharmacy Benefit Management Services Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Type (USD Billion)
  49.     4.1.1 Claims Management
  50.     4.1.2 Formulary Management
  51.     4.1.3 Drug Utilization Review
  52.     4.1.4 Medication Therapy Management
  53.   4.2 Life Sciences, BY End User (USD Billion)
  54.     4.2.1 Pharmacies
  55.     4.2.2 Health Plans
  56.     4.2.3 Employers
  57.     4.2.4 Public Sector
  58.   4.3 Life Sciences, BY Service Provider (USD Billion)
  59.     4.3.1 Standalone Pharmacy Benefit Managers
  60.     4.3.2 Health Insurance Companies
  61.     4.3.3 Integrated Health Systems
  62.   4.4 Life Sciences, BY Operating Model (USD Billion)
  63.     4.4.1 Fully-Managed Services
  64.     4.4.2 Pass-Through Services
  65.     4.4.3 Hybrid Services
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Life Sciences
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 CVS Health (US)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Express Scripts (US)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 OptumRx (US)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Humana (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 Cigna (US)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Prime Therapeutics (US)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 MedImpact (US)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 EnvisionRx (US)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.   5.3 Appendix
  131.     5.3.1 References
  132.     5.3.2 Related Reports
  133. 6 LIST OF FIGURES
  134.   6.1 MARKET SYNOPSIS
  135.   6.2 GERMANY MARKET ANALYSIS BY TYPE
  136.   6.3 GERMANY MARKET ANALYSIS BY END USER
  137.   6.4 GERMANY MARKET ANALYSIS BY SERVICE PROVIDER
  138.   6.5 GERMANY MARKET ANALYSIS BY OPERATING MODEL
  139.   6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
  140.   6.7 RESEARCH PROCESS OF MRFR
  141.   6.8 DRO ANALYSIS OF LIFE SCIENCES
  142.   6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  143.   6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  144.   6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  145.   6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
  146.   6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Billion)
  147.   6.14 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
  148.   6.15 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Billion)
  149.   6.16 LIFE SCIENCES, BY SERVICE PROVIDER, 2024 (% SHARE)
  150.   6.17 LIFE SCIENCES, BY SERVICE PROVIDER, 2024 TO 2035 (USD Billion)
  151.   6.18 LIFE SCIENCES, BY OPERATING MODEL, 2024 (% SHARE)
  152.   6.19 LIFE SCIENCES, BY OPERATING MODEL, 2024 TO 2035 (USD Billion)
  153.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  154. 7 LIST OF TABLES
  155.   7.1 LIST OF ASSUMPTIONS
  156.     7.1.1
  157.   7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  158.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  159.     7.2.2 BY END USER, 2025-2035 (USD Billion)
  160.     7.2.3 BY SERVICE PROVIDER, 2025-2035 (USD Billion)
  161.     7.2.4 BY OPERATING MODEL, 2025-2035 (USD Billion)
  162.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  163.     7.3.1
  164.   7.4 ACQUISITION/PARTNERSHIP
  165.     7.4.1

Germany Life Sciences Market Segmentation

Life Sciences By Type (USD Billion, 2025-2035)

  • Claims Management
  • Formulary Management
  • Drug Utilization Review
  • Medication Therapy Management

Life Sciences By End User (USD Billion, 2025-2035)

  • Pharmacies
  • Health Plans
  • Employers
  • Public Sector

Life Sciences By Service Provider (USD Billion, 2025-2035)

  • Standalone Pharmacy Benefit Managers
  • Health Insurance Companies
  • Integrated Health Systems

Life Sciences By Operating Model (USD Billion, 2025-2035)

  • Fully-Managed Services
  • Pass-Through Services
  • Hybrid Services

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓